Mid-Year Report

CEPHALON, INC. for CEPHALON INC

Firm
Client
Income
—
Expenses
$531,219

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

H.Con.Res 95. Support for additional FDA resources. Support for funds for SAMHSA.

LobbyistCovered position, as disclosed
JENNIFER MICHELE CONNELLY N/A
JEFF M MYERS N/A
KIM ZIMMERMAN N/A

Contacted: Substance Abuse & Mental Health Services Administration (SAMHSA); SENATE; Natl Institutes of Health (NIH); Drug Enforcement Administration (DEA); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.Con.Res. 95 (110th)

Health Issues HCR

P.L. 109-57, implementation of export regulations for controlled substances. S. 3807, Sens Enzy, Kennedy, Drug Safety legislation, "Enhancing Drug Safety and Innovation Act of 2006." Section 1. riskmaps; section 4. Advisory committees; approval standards for pharmaceuticals. H.R. 3162 SCHIP; H.R. 4, Medicare Prescription Drug Price Negotiation Act of 2007

LobbyistCovered position, as disclosed
JENNIFER MICHELE CONNELLY N/A
JEFF M MYERS N/A
KIM ZIMMERMAN N/A

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Drug Enforcement Administration (DEA); Substance Abuse & Mental Health Services Administration (SAMHSA); Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); Food & Drug Administration (FDA)

Bills named: S. 3807 (110th), H.R. 4 (110th), H.R. 3162 (110th)

Copyright/Patent/Trademark CPT

H.R. 2795, Patent Reform Act. Provisions related to pharmaceutical patents. H.R. 5418, Establishing a pilot program for patent cases; S. 3582, Preserve Access to Affordable Generics Act; H.R. 1432, To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market. H.R. 2642, Military Construction and Veteran's Affairs Appropriations Act, 2008.

LobbyistCovered position, as disclosed
JENNIFER MICHELE CONNELLY N/A
JEFF M MYERS N/A
KIM ZIMMERMAN N/A

Contacted: Drug Enforcement Administration (DEA); Natl Institutes of Health (NIH); Substance Abuse & Mental Health Services Administration (SAMHSA); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1432 (110th), S. 3582 (110th), H.R. 5418 (110th), H.R. 2795 (110th), H.R. 2642 (110th)

Alcohol and Drug Abuse ALC

Support for standards for new pharmaceuticals therapies for the treatment of alcoholism.

LobbyistCovered position, as disclosed
JENNIFER MICHELE CONNELLY N/A
JEFF M MYERS N/A
KIM ZIMMERMAN N/A

Contacted: Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Substance Abuse & Mental Health Services Administration (SAMHSA); Centers For Medicare and Medicaid Services (CMS); SENATE; Drug Enforcement Administration (DEA); Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.